A fusion protein being a lipid-free reference standard having good long-term storability, which is used for measuring the quantity or quality of modified HDL, and a method for accurately, repeatability and reliably measuring high-density lipoprotein using the same. In the fusion protein, a complete protein sequence or partial fragment protein sequence for ApoA I is linked directly or via a spacer to a LOX-1 binding protein sequence that binds to a lectin-like oxidized LDL receptor: LOX-1. The method for measuring a modified high-density lipoprotein in a test sample is a method for measuring a modified high-density lipoprotein through binding of the modified high-density lipoprotein to LOX-1 and an anti-APOA I antibody, wherein, using the fusion protein as a reference standard for the modified high-density lipoprotein, the modified high-density lipoprotein in the test sample is determined by comparison with the reference standard through optical detection and/or radiation dosage detection.

A fusion protein being a lipid-free reference standard having good long-term storability, which is used for measuring the quantity or quality of modified HDL, and a method for accurately, repeatability and reliably measuring high-density lipoprotein using the same. In the fusion protein, a complete protein sequence or partial fragment protein sequence for ApoA I is linked directly or via a spacer to a LOX-1 binding protein sequence that binds to a lectin-like oxidized LDL receptor: LOX-1. The method for measuring a modified high-density lipoprotein in a test sample is a method for measuring a modified high-density lipoprotein through binding of the modified high-density lipoprotein to LOX-1 and an anti-APOA I antibody, wherein, using the fusion protein as a reference standard for the modified high-density lipoprotein, the modified high-density lipoprotein in the test sample is determined by comparison with the reference standard through optical detection and/or radiation dosage detection.

Provided herein are methods for purifying proteins from mixtures of proteins using ultrafiltration, such as tangential-flow filtration (TFF). Provided herein are methods for isolating an apoprotein from a protein solution comprising a conjugated protein, wherein the conjugated protein comprises the apoprotein and a hydrophobic ligand associated with the apoprotein.

Synthetic apolipoproteins based on native/naturally occurring homolog proteins can be prepared using solid-phase peptide synthesis approaches combined with native chemical ligation methods to create analogs of full length apolipoproteins. The chemical synthesis is expected to allow introduction of non-natural amino acids, e.g., α,α′-dialkyl amino acids, with a periodicity that encourages both helix formation and amphipathicity. Such apolipoprotein analogs are expected to encourage, in some embodiments, facile and more complete NLP formation, enabling consideration of full spectrum of nanoparticle-based biotechnology applications ranging from therapeutic sequestration and delivery to energy/biofuel production to biopolymer production.

Synthetic apolipoproteins based on native/naturally occurring homolog proteins can be prepared using solid-phase peptide synthesis approaches combined with native chemical ligation methods to create analogs of full length apolipoproteins. The chemical synthesis is expected to allow introduction of non-natural amino acids, e.g., α,α′-dialkyl amino acids, with a periodicity that encourages both helix formation and amphipathicity. Such apolipoprotein analogs are expected to encourage, in some embodiments, facile and more complete NLP formation, enabling consideration of full spectrum of nanoparticle-based biotechnology applications ranging from therapeutic sequestration and delivery to energy/biofuel production to biopolymer production.

Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).

Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).

There is a method of separating phosvitin and HDL proteins from an egg yolk composition. The egg yolk composition includes HDL proteins bound to phosvitin. At least a portion of the HDL proteins are hydrolysed to cause the HDL proteins and phosvitin to become unbound and forming a hydrolysed solution comprising hydrolysed HDL, phosvitin and peptides. The hydrolysed HDL is separated from the phosvitin and peptides to form a separated hydrolysed HDL composition and a separated phosvitin and peptide solution. One resulting product is an egg yolk composition formed having at least 20% solids by mass of phosvitin phosphopeptides unbound from HDL. Another resulting product is an egg yolk composition having at least 80% hydrolysed HDL-derived lipopeptide solids by mass.

The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.

The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.